Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002111
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Dose-Escalating Study of Ro 31-8959 HIV Protease Inhibitor in Patients With HIV Disease
Sponsor:
Stanford University
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Dose-Escalating Study of Ro 31-8959 HIV Protease Inhibitor in Patients With HIV Disease
Status:
COMPLETED
Status Verified Date:
1995-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate the toxicity antiviral activity and pharmacokinetics in HIV-infected patients receiving 16 weeks of oral saquinavir mesylate Ro 31-8959 at one of two doses
Detailed Description:
Cohorts of 16 patients receive 1 of 2 doses of Ro 31-8959 for 20 weeks Administration of the higher dose will proceed only after 2-week safety data for the first eight patients on the lower dose has been reviewed
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EV 14757 | None | None | None |